RxDoctor Payments Data

Omar Gomez, MD

Internal Medicine · Pharr, TXNPI 1871667493

Payments from drug & device makers

$156,125in general payments, 2019–2025

Across 31 payments — averaging $5036.29 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Exact Sciences$155K
  • Novartis$137
  • Johnson & Johnson$125
  • Lilly USA, LLC$124
  • Boehringer Ingelheim$116
  • Paratek Pharmaceuticals, Inc.$103
  • plus $304 from 4 others

What the payments were for

  • Food & beverage$82391%
  • Education$859%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

20
21
22
23
24

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$156,125 in reported general payments places this provider in the 95th percentile of 7,675 internal medicine providers in Texas.

See all internal medicine providers in Texas

Medicare billing

Part B allowed, 2024
$8,848
Medicare patients
31
Services billed
89

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide141$188,874
JardianceEmpagliflozin117$174,349
MounjaroTirzepatide83$142,662
FarxigaDapagliflozin Propanediol61$75,161
MyrbetriqMirabegron86$71,276
RybelsusSemaglutide31$66,830
EliquisApixaban38$63,364
VascepaIcosapent Ethyl85$62,493
VeltassaPatiromer Calcium Sorbitex39$60,576
JanuviaSitagliptin Phosphate41$58,692
TrulicityDulaglutide29$56,578
XareltoRivaroxaban34$56,489
GemtesaVibegron51$50,164
LinzessLinaclotide50$40,960
Trelegy ElliptaFluticasone/Umeclidin/Vilanter45$39,591

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Boehringer IngelheimJardiance, Synjardy Xr, Tradjenta, Synjardy$116$246,091177 claims
Lilly USA, LLCMounjaro, Trulicity$124$199,239112 claims
AbbVieLinzess, Vraylar$38$72,87266 claims
Astellas Pharma US IncMyrbetriq$85$71,27686 claims
Johnson & JohnsonXarelto$125$56,48934 claims
NovartisEntresto$137$25,99315 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 7,675 internal medicine providers in Texas.

Other internal medicine in Pharr

See the full list for Texas

Where these figures come from

Is this you, or does something look wrong? →